Name: Tesamorelin - 10mg
SKU: 107-1
Availability: InStock

Tesamorelin – 10mg

As Low as: $76.30 /per vial

Tesamorelin is a synthetic analogue of human growth hormone-releasing hormone (GHRH), specifically a modified version of the naturally occurring GHRH peptide. It consists of 44 amino acids and has been engineered to provide enhanced stability and a prolonged half-life in the body compared to endogenous GHRH. This modification allows for more sustained and consistent stimulation of the pituitary gland’s somatotroph cells.

$130.00 – $7,630.00

Submit Request

SKU: 107-1 Category:Lyophilized

Description

Quick Facts

Tesamorelin acts by binding to and activating specific GHRH receptors on the pituitary gland. This binding stimulates the pituitary to synthesize and secrete endogenous growth hormone (GH) in a pulsatile, physiological manner. Unlike exogenous growth hormone, Tesamorelin works by enhancing the body’s natural GH production and release, leading to an increase in circulating GH and, consequently, insulin-like growth factor 1 (IGF-1) levels. Its targeted action ensures that the body’s own regulatory mechanisms for GH secretion remain largely intact.

Metabolic Disorders: Tesamorelin is extensively investigated for its role in modulating body composition, particularly in reducing excess visceral adipose tissue (VAT) in various research models.
Lipodystrophy: Studies focus on its potential to address abnormal fat distribution, especially in conditions characterized by visceral fat accumulation.
Cardiovascular Health: Research explores the impact of improved body composition and metabolic parameters on cardiovascular risk factors.
Cognitive Function: Emerging research suggests potential influences on cognitive function and neural health, though these areas are still under active investigation.
General Health & Aging: Its ability to stimulate natural GH release makes it a subject of interest in broader studies concerning metabolic health and aspects of aging.

Why Choose Peptide Chains for Tesamorelin?

Peptide Chains provides high-purity Tesamorelin in bulk API quantities, optimized for your research and development needs. Our Tesamorelin is lyophilized for excellent stability and meticulously tested to ensure exceptional purity and consistency, crucial for reliable and reproducible scientific outcomes. For researchers and pharmaceutical developers focusing on metabolic health, body composition, and natural hormone modulation, our Tesamorelin offers the quality assurance and consistent supply necessary to advance your projects with confidence.

Additional information

Weight	0.05 lbs
Dimensions	10 × 15 × 5 in
Vial Quantity	Order a Sample, 10, 20, 50, 100

Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data

Abstract

Context: HIV patients treated with antiretroviral therapy (ART) often develop increased visceral adipose tissue (VAT).

Objective: Our objective was to perform a pooled analysis of two phase-3 studies of tesamorelin in ART-treated HIV patients with excess abdominal fat.

Design and setting: Two multicenter, international studies were conducted; a 26-wk randomized, placebo-controlled primary intervention phase was followed by a 26-wk safety extension.

Patients: A total of 806 ART-treated HIV patients with excess abdominal fat were randomized in a 2:1 fashion to receive tesamorelin 2 mg (n = 543) or placebo (n = 263) sc daily. At wk 26, patients initially on tesamorelin were rerandomized to 2 mg tesamorelin (T-T group, n = 246) or placebo (T-P, n = 135) for an additional 26 wk, whereas patients on placebo were switched to tesamorelin (P-T, n = 197).

Interventions: Tesamorelin (GHRH(1-44)) at a dose of 2 mg or identical placebo, sc, was given daily.

Main outcome measure: We evaluated percent change in VAT by computed tomography scan at wk 26.

Results: At wk 26, VAT decreased significantly in tesamorelin-treated patients (-24 +/- 41 vs. 2 +/- 35 cm(2), tesamorelin vs. placebo, P < 0.001; treatment effect, -15.4%). No significant changes were observed in abdominal sc adipose tissue (-2 +/- 32 vs. 2 +/- 29 cm(2), P = 0.08; treatment effect, -0.6%). Treatment with tesamorelin resulted in significant decreases in triglycerides (-37 +/- 139 vs. 6 +/- 112 mg/dl, P < 0.001; treatment effect, -12.3%) and cholesterol to high-density lipoprotein ratio (-0.18 +/- 1.00 vs. 0.18 +/- 0.94, P < 0.001; treatment effect, -7.2%) vs. placebo. Tesamorelin improved body image [belly appearance distress (P = 0.002)], patient rating of belly profile (P = 0.003), and physician rating of belly profile (P < 0.001). Mean IGF-I increased 108 +/- 112 vs.-7 +/- 64 ng/ml (P < 0.001 vs. placebo). At wk 52, decreases in VAT [-35 +/- 50 cm(2) (-17.5 +/- 23.3%)], waist circumference (-3.4 +/- 6.0 cm), triglycerides (-48 +/- 182 mg/dl), cholesterol (-8 +/- 38 mg/dl), and non-high-density lipoprotein (-7 +/- 38 mg/dl) were maintained (all P < 0.001 vs. original baseline) in the T-T group. Treatment with tesamorelin was generally well tolerated. No clinically meaningful differences were observed between groups in glucose parameters at wk 26 and 52.

Conclusions: Treatment with tesamorelin reduces VAT and maintains the reduction for up to 52 wk, preserves abdominal sc adipose tissue, improves body image and lipids, and is overall well tolerated without clinically meaningful changes in glucose parameters.